We are a state-of-the-art clinical laboratory committed to providing accurate and timely test results to healthcare providers and patients. Our team of experienced professionals uses the latest technology and techniques to ensure the highest quality testing. With those laboratory results, combined with demographics, lifestyle, environmental, and behavioral factors, Proove Genomics performs advanced mathematics using algorithms to assess patient care and provide those insights to ordering clinicians. Thank you for choosing Proove Genomics for your Personalized Pain Medicine needs.
Vision of Proove Genomics
Advanced Molecular Diagnostic Testing Panels
Objectively Assess Patient Pain Thresholds and the Role of Central Pain Perception to Guide Patient Care
Objectively Assess Patient Risk for Opioid Use Disorder (OUD) to Appropriately Prescribe Opioids and Protect those Patients At-Risk
Objectively Assess Patient Risk for NSAID-Mediated Side Effects to Guide use of NSAID therapy
Pharmacogenetic test of a Patient's drug-metabolism to various classes of medications, including pain, psychotropic, cardiovascular, and more
Confirmatory Mass Spectrometry Testing of Medication Adherence and Aberrant Behavior
Toxicology confirmatory test that evaluates the presence of substances expected and unexpected, along with phenotypic factors influencing the results
Disclaimer: These test(s) have not be cleared or approved by the United States Food and Drug Administration (FDA). The performing laboratory has validated the performance characteristics of the above test(s). The above test(s) results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Only medically necessary tests (based on specific patient diagnosis and treatment) should be ordered.
In a number of published studies involving over 13,000 patients across orthopedic, pain management, and primary care clinics, Proove's Personalized Pain Medicine Panels result in substantial clinical utility. Clinicians rate the testing very valuable, with 88%-90% of clinicians believing that the testing provided benefits to patients. The average patient had pain reductions in excess of what is established by experts and the U.S. Food and Drug Administration as a minimal clinically important difference in their pain scale.
If you have any questions or would like to schedule an appointment with someone on our mission-driven team, we invite you to reach out to us and share your area of interest.